2 completed, 2 recruiting, 1 active not recruiting. 3 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Phase 3 | 2 | Recruiting 2 |
| Phase 1 | 1 | Completed 1 |
Follow TR Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tissue Repair Gel in Venous Leg Ulcers in AU/US TR987 0.1% gel + Standard of Care, Standard of care - Venous Leg Ulcer, Venous Ulcer | Phase 3 | Recruiting | TR Therapeutics | 312 | 2025-04-01 | 2025-04-02 |
| Tissue Repair Gel in Venous Leg Ulcers (US) TR987 0.1% gel + Standard of Care, Standard of care - Venous Leg Ulcer, Venous Ulcer | Phase 3 | Recruiting | TR Therapeutics | 312 | 2025-01-28 | 2026-02-12 |
| Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers 0.1% TR 987, Placebo gel - Venous Leg Ulcer | Phase 2 | Active not recruiting | SerenaGroup, Inc. | 80 | 2016-11-01 | 2020-10-22 |
| Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation GLYC-101 Gel (0.1%), GLYC-101 Gel (1.0%), GLYC-101 Placebo - Wounds | Phase 2 | Completed | TR Therapeutics | 26 | 2008-10-01 | 2021-10-28 |
| Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation Placebo gel, GLYC-101 gel (1.0 %) - Wounds | Phase 1 / Phase 2 | Completed | TR Therapeutics | 12 | 2008-03-01 | 2021-10-28 |
Wounds and Injuries (4) · Varicose Ulcer (3) · Burns (2)
Gels (2) · Standard of Care (2) · beta-Glucans (1)
United States (5) · Australia (1)
John Joseph, MD (2) · Thomas Serena, MD (1)